Japan's Ministry of Health, Labour and Welfare approves Vadadustat for anemia caused by chronic kidney disease
-
Last Update: 2020-07-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Biopharmaceutical company Akebia Therapeutics announced today that Japan's Ministry of Health, Labour and Welfare has approved the hypoxic-induced factor oxalate oxytoxe inhibitor vadadustat for the treatment of anemia caused by chronic kidney disease (CKD)Akebia's partner Mitsubishi Tianbian Pharmaceuticals (MTPC) has obtained a license to manufacture and sell vadadustat, which will be sold by MTPC in Japan under the commodity name VAFSEOabout 13 million people in Japan,, have advanced CKDAnemia is common in CKD patients and increases with the development of CKDIn addition to causing disabling symptoms, severe anemia may affect the function ofcardiovascularin non-dialysis CKD patients and dialysis patientsFor non-dialysis CKD patients, severe anemia may accelerate the progression of end-stage renal disease (end-stage renal disease, ESRD)Injection erythroms (ESA) are current standardof careVadadustat will provide a convenient oral treatment for adult patientsJohn PButler, President and CEO of Akebia, said, "For patients with anaemia caused by CKD, the approval of Vadadustat will be of significant benefit to Japanese patientsVadadustat is expected to be commercialized in Japan later this year."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
